Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment
暂无分享,去创建一个
J. Fisher | G. Henderson | R. J. Cadigan | J. Ananworanich | K. Meagher | N. Phanuphak | H. Peay | N. Chomchey | E. Kroon | S. Rennie | A. Gilbertson | T. Jupimai | N. Ormsby
[1] J. Ananworanich,et al. Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations , 2017, Journal of virus eradication.
[2] A. Skinner,et al. 'Well, It's the Risk of the Unknown… Right?': A Qualitative Study of Perceived Risks and Benefits of HIV Cure Research in the United States , 2017, PloS one.
[3] David Evans,et al. An activist's argument that participant values should guide risk–benefit ratio calculations in HIV cure research , 2017, Journal of Medical Ethics.
[4] D. Resnik. The Role of Intuition in Risk/Benefit Decision-Making in Human Subjects Research , 2017, Accountability in research.
[5] A. Skinner,et al. Willingness to participate and take risks in HIV cure research: survey results from 400 people living with HIV in the US , 2017, Journal of virus eradication.
[6] G. Treisman,et al. Neuropsychiatric Effects of HIV Antiviral Medications , 2016, Drug Safety.
[7] D. Wikler. Must research benefit human subjects if it is to be permissible? , 2016, Journal of Medical Ethics.
[8] Jerome H. Kim,et al. Initiation of Antiretroviral Therapy During Acute HIV-1 Infection Leads to a High Rate of Nonreactive HIV Serology. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] Barton F. Haynes,et al. Latency reversal and viral clearance to cure HIV-1 , 2016, Science.
[10] Richard Jefferys,et al. International AIDS Society global scientific strategy: towards an HIV cure 2016 , 2016, Nature Medicine.
[11] S. Lewin,et al. OA3-5 LB Effect of vorinostat, hydroxychloroquine and maraviroc combination therapy on viremia following treatment interruption in individuals initiating ART during acute HIV infection , 2016 .
[12] Lara Buchak. Why high-risk, non-expected-utility-maximising gambles can be rational and beneficial: the case of HIV cure studies , 2016, Journal of Medical Ethics.
[13] N. Eyal. How to keep high-risk studies ethical: classifying candidate solutions , 2016, Journal of Medical Ethics.
[14] N. Eyal. The benefit/risk ratio challenge in clinical research, and the case of HIV cure: an introduction , 2016, Journal of Medical Ethics.
[15] E. Largent. For love and money: the need to rethink benefits in HIV cure studies , 2016, Journal of Medical Ethics.
[16] R. Dresser. First-in-human HIV-remission studies: reducing and justifying risk , 2016, Journal of Medical Ethics.
[17] S. Lewin,et al. Ethics of ART interruption after stem-cell transplantation. , 2016, The lancet. HIV.
[18] J. Mellors,et al. Cellular HIV RNA/DNA as biomarkers of inducible virion production , 2015 .
[19] R. Phillips,et al. Immunological biomarkers predict HIV-1 viral rebound after treatment interruption , 2015, Nature Communications.
[20] P. Appelbaum,et al. Why is therapeutic misconception so prevalent? , 2015, Cambridge quarterly of healthcare ethics : CQ : the international journal of healthcare ethics committees.
[21] G. Henderson. The ethics of HIV "cure" research: what can we learn from consent forms? , 2015, AIDS research and human retroviruses.
[22] G. Henderson,et al. What motivates participation in HIV cure trials? A call for real-time assessment to improve informed consent , 2015, Journal of virus eradication.
[23] D. Hunter. The right to participate in high-risk research , 2014, The Lancet.
[24] J. Tucker,et al. Social and ethical implications of HIV cure research , 2014, AIDS.
[25] S. Lewin,et al. The end of AIDS: HIV infection as a chronic disease , 2013, The Lancet.
[26] D. Kuritzkes,et al. Challenges in clinical trial design for HIV-1 cure research , 2013, The Lancet.
[27] J. Sugarman. HIV Cure Research: Expanding the Ethical Considerations , 2013, Annals of Internal Medicine.
[28] R. Rawbone. The Oxford Textbook of Clinical Research Ethics , 2013 .
[29] C. Grady,et al. Ethical considerations in HIV cure research: points to consider , 2013, Current opinion in HIV and AIDS.
[30] D. Richman,et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. , 2013, The New England journal of medicine.
[31] Michael Rayment,et al. Prevention of HIV-1 infection with early antiretroviral therapy , 2012, Journal of Family Planning and Reproductive Health Care.
[32] Jerome H. Kim,et al. Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection , 2012, PloS one.
[33] D. Wendler,et al. Which Benefits of Research Participation Count as ‘Direct’? , 2012, Bioethics.
[34] 遠藤 知之. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention , 2011 .
[35] M. Weeks,et al. Altruism and Peer-Led HIV Prevention Targeting Heroin and Cocaine Users , 2010, Qualitative health research.
[36] Ezekiel J. Emanuel,et al. The Oxford Textbook of Clinical Research Ethics , 2008 .
[37] L. Reid,et al. The Harm-Benefit Tradeoff in “Bad Deal” Trials , 2008, Kennedy Institute of Ethics journal.
[38] C. Grady,et al. Clinical Trials and Medical Care: Defining the Therapeutic Misconception , 2007, PLoS medicine.
[39] O. Corrigan,et al. Empty ethics: the problem with informed consent. , 2003, Sociology of health & illness.
[40] W. H. Dobelle,et al. Altruism and the volunteer: psychological benefits from participating as a research subject. , 2001, ASAIO journal.
[41] N. King. Defining and Describing Benefit Appropriately in Clinical Trials , 2000, Journal of Law, Medicine & Ethics.
[42] J. Lantos. The "inclusion benefit" in clinical trials. , 1999, The Journal of pediatrics.